Cancer Diagnostics Company - Pre-IPO Existing Shareholding

Cancer Diagnostics Company - Pre-IPO Existing Shareholding - FDA Listed ISO13485 Certified

Categories:	Securities, Pre-IPO / Grey Market
Sale Type:	Asking Price
Price Guide:	AUD 6M shares @ $0.14 per share (cum rights) = 24.32% discount to December 2016 Pre-IPO Rights Issue
Status:	Closed

Summary:

Sale of pre-IPO existing shares by a motivated Seller in a public, unlisted Company based in Melbourne, Australia. Since 2007, the Company has successfully realised IP value in telomerase-based diagnostics to effectively identify bladder cancer. In 2016 it transitioned from a purely R&D company to a commercial entity with product revenues. Has recently formalised distribution agreements for US and UK markets. Since inception, the Company has raised A$16.1M in equity to successfully achieve milestones and has been well supported by considerable R&D Incentives.